Role of Myc in hepatocellular proliferation and hepatocarcinogenesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background & Aims MYC is involved in cell growth, proliferation, apoptosis, energy metabolism, and differentiation. Whether it is essential for hepatocellular proliferation and carcinogenesis is unclear due to a lack of an efficient hepatocyte-specific Myc disruption model. This study used a novel genetic model to investigate the involvement of MYC in hepatocellular proliferation and hepatocarcinogenesis in mice. Methods Temporal hepatocyte-specific Myc disruption was achieved by use of the tamoxifen-inducible Cre-ERT2 recombinase system under control of the serum albumin promoter. Hepatocyte proliferation was assessed by administering peroxisome proliferator-activated receptor α(PPARα) agonist Wy-14,643. A diethylnitrosamine-induced liver cancer model was used to evaluate the role of Myc in hepatocarcinogenesis. Results Tamoxifen administration induced recombination of Myc specifically in hepatocytes of Mycfl/fl,ERT2-Cre mice. When treated with a known hepatocellular proliferative stimulus Wy-14,643, Mycfl/fl,ERT2-Cre mice showed a lower liver/body weight ratio and suppressed hepatocyte proliferation as compared to Mycfl/fl mice. Hepatic expression of cell cycle control genes, DNA repair genes, and Myc target gene miRNAs were upregulated in Wy-14,643-treated Mycfl/fl mouse livers, but not in Wy-14,643-treated Mycfl/fl,ERT2-Cre livers. However, no differences were observed in the lipid-lowering effect of Wy-14,643 between Mycfl/fl,ERT2-Cre and Mycfl/fl mice, consistent with no differences in the expression of several PPAR α target genes involved in fatty acid β-oxidation. Moreover, when subjected to the diethylnitrosamine liver cancer bioassay, Mycfl/fl,ERT2-Cre mice exhibited a markedly lower incidence of tumor formation compared with Mycfl/fl mice. Conclusion Myc plays an essential role in hepatocellular proliferation and liver tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“Fibrate drugs used to lower plasma triglycerides [26], are agonist for PPARa, a ligand-activated nuclear receptor that controls genes involved in fatty acid transport and catabolism, primarily in liver, but also in kidney, heart and skeletal muscle [27,28].”
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625 · cited 1×
“CHEK1 kinase acts downstream of ATM/ATR kinase and plays an important role in DNA damage checkpoint control, embryonic development and tumor suppression [35,36].”
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“Dysregulation of Myc is commonly found in several cancers [7–9].”
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874 · cited 2×
“In liver, constitutive overexpression of Myc induces tumorigenesis, whereas inhibition of Myc expression resulted in regression of established tumors in vivo [11,12], indicating that targeting Myc is a potential approach for therapeutics of liver tumors.”
Hu, S., Balakrishnan, A., Bok, R. A., Anderton, B., Larson, P. E. Z., Nelson, S. J., Kurhanewicz, J., Vigneron, D. B., & Goga, A. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.012 · Cited by 245
c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver
Baena, E., Gandarillas, A., Vallespinós, M., Zanet, J., Bachs, O., Redondo, C., Fabregat, I., Martinez-A., C., & de Alborán, I. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409260102 · Cited by 104 · cited 2×
“Previously, other groups targeted Myc disruption in liver [22,23].”
Cited by
Umemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., Font-Burgada, J., Zhong, Z., Subramaniam, S., Raghunandan, S., Duran, A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.006 · Cited by 463
Wang, H., Zhang, H., Wang, Y., Brown, Z. J., Xia, Y., Huang, Z., Shen, C., Hu, Z., Beane, J., Ansa-Addo, E. A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.032 · Cited by 398
Goetzman, E. S., & Prochownik, E. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00129 · Cited by 199
The PPARα-Dependent Rodent Liver Tumor Response Is Not Relevant to Humans: Addressing Misconceptions
Corton, J. C., Peters, J. M., & Klaunig, J. E. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2094-7 · Cited by 175
Brocker, C. N., Yue, J., Kim, D., Qu, A., Bonzo, J. A., & Gonzalez, F. J. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00205.2016 · Cited by 93
“These data support previous studies that indicate agonist-induced hepatomegaly activates DNA damage-related pathways (38, 39).”
ResultSelf-citation
Metadata
- Authors
- Qu, A., Jiang, C., Cai, Y., Kim, J.-H., Tanaka, N., Ward, J. M., Shah, Y. M., & Gonzalez, F. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 60
- Issue
- 2
- Pages
- 331-338
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1992581344
- Cited by
- 80
- References
- 8
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.